On the cost-effectiveness of dabigatran. Response.
Servicio de Cardiología, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
José R
JR
González-Juanatey
Servicio de Cardiología, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.
Antoni
A
Martínez-Rubio
Departamento de Economía y Resultados en Salud, Boehringer Ingelheim, Barcelona, Spain. Electronic address: nuria.gonzalez-rojas@boehringer-ingelheim.com.
Nuria
N
González-Rojas
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D015091:beta-Alanine / Q000031:analogs & derivatives*
D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014812:Vitamin K